AmpliMed to Present at Rodman & Renshaw 7th Annual Healthcare Conference.TUCSON, Ariz. -- AmpliMed(TM) today announced that Robert Ashley, chairman, president and chief executive officer, will be giving a presentation at the Rodman & Renshaw 7th Annual Healthcare Conference 2005. Mr. Ashley's presentation is scheduled for Tuesday, November 8 at 4:55 p.m. ET in the Kennedy I room at the New York Palace
New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . AmpliMed is a privately-owned pharmaceutical company dedicated to the development of novel cancer chemotherapies. Mr. Ashley will be providing an overview of the company, highlighting the progress of the clinical trials for its lead drug candidate, Amplimexon(R) (imexon inj.). About Amplimexon(R) Amplimexon is AmpliMed's trademarked name for imexon injection, an injectable formulation of a cyanoaziridine compound which showed tantalizing tan·ta·lize tr.v. tan·ta·lized, tan·ta·liz·ing, tan·ta·liz·es To excite (another) by exposing something desirable while keeping it out of reach. evidence of activity in limited studies in lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. , melanoma and breast cancer that were documented in publications in the 1980s. The potential of imexon as a cancer drug was never fully explored, until 1994, when AmpliMed co-founding scientists Drs. Evan Hersh, David Alberts, Robert Dorr and William Remers initiated a program to decipher Amplimexon's novel mechanism of action. They discovered that the drug disrupted mitochondria, the energy producing factories of the cancer cells, resulting in the leakage of toxic substances which ultimately resulted in cell death. This led to the initiation in 2003 of an ongoing Phase I clinical study of the drug as a stand-alone therapy in late-stage cancer patients. Further preclinical research revealed that the combined use of Amplimexon and certain other chemotherapeutics resulted in a significant increase in efficacy compared to either drug alone. These findings are now being translated into a series of Phase I/II clinical studies of combination therapy in patients with various types of cancer. The first two of these, in which Amplimexon is combined with gemcitabine in patients with untreated pancreatic adenocarcinoma adenocarcinoma: see neoplasm. and with dacarbazine (DTIC DTIC A trademark for the drug dacarbazine. DTIC dacarbazine. dacarbazine Warning - Hazardous drug! DTIC (CA), DTIC-Dome ) in patients with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. malignant melanoma Malignant Melanoma Definition Malignant melanoma is a type of cancer arising from the melanocyte cells of the skin. Melanocytes are cells in the skin that produce a pigment called melanin. are currently underway. About AmpliMed Corporation AmpliMed Corporation was founded in 1989 with the support of the University of Arizona (body, education) University of Arizona - The University was founded in 1885 as a Land Grant institution with a three-fold mission of teaching, research and public service. Technology Development Corporation and is focused on the clinical development of chemotherapeutic agents for cancer. AmpliMed's strategy is to develop anti-cancer drugs with novel mechanisms of action designed to overcome some of the limitations, such as myelosuppression (suppression of blood cell counts), multi-drug resistance (treatment-induced resistance to many cancer drugs) and cardiac toxicity, frequently associated with current cancer therapy. The company's lead product, Amplimexon(R) (imexon inj.), is undergoing NDA-directed clinical development. Other products in the company's portfolio include Amplizone(TM) and Carbendazim, both of which are expected to enter the clinic in 2006, and a portfolio of derivatives of each of the lead compounds for future development. AmpliMed Corporation is based in Tucson, Arizona and is on the Web at http://www.amplimed.com. AmpliMed, Amplimexon and Amplizone are United States trademarks of AmpliMed Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion